Skip to main content
Premium Trial:

Request an Annual Quote

Florida Atlantic University, Torrey Pines to Test Compounds for Cancer Drug Development

NEW YORK  (GenomeWeb News) — Florida Atlantic University and Torrey Pines Institute for Molecular Studies plan to study compounds discovered by TPIMS with an FAU genetic discovery related to three major cancers, FAU said yesterday.
 
Under the agreement, FAU and TPIMS will use a gene called SIM2, which has been associated with colon, prostate, and pancreatic cancers, at FAU’s Charles E. Schmidt College of Science to develop drugs.  
 
FAU said researchers at the CSCS have co-developed an assay to discover an inhibitor of the SIM2 gene, which will be screened against “thousands of compounds from TPIMS’ collection” for usefulness as a therapy.
 
FAU said the researchers will use Affymetrix’s GeneChip microarrays for the analysis.
 
According to CSCS, FAU “has the basic research and proof-of-concept in place,” and TPIMS has “the compounds and expertise to help expedite drug discovery.”

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.